Literature DB >> 10685870

K(ATP) channel blocker HMR 1883 reduces monophasic action potential shortening during coronary ischemia in anesthetised pigs.

K J Wirth1, J Uhde, B Rosenstein, H C Englert, H Gögelein, B A Schölkens, A E Busch.   

Abstract

ATP-sensitive potassium channels (KATP) open during myocardial ischemia. The ensuing repolarising potassium efflux shortens the action potential. Accumulation of extracellular potassium is able to partially depolarise the membrane, reducing the upstroke velocity of the action potential and thereby impairing impulse conduction. Both mechanisms are believed to be involved in the development of reentrant arrhythmias during cardiac ischemia. The sulfonylthiourea HMR 1883 (1-[[5-[2-(5-chloro-O-anisamido)ethyl]-methoxyphenyl]sulfonyl]-3-m ethylthiourea) was designed as a cardioselective KATP channel blocker for the prevention of arrhythmic sudden death in patients with ischemic heart disease. The aim of this study was to show that this compound, which has already shown antifibrillatory efficacy in dogs and rats, is able to inhibit ischemic changes of the action potential induced by coronary artery occlusion in anesthetised pigs. Action potentials were taken in situ with the technique of monophasic action potential (MAP) recording. In a control group (n=7), three consecutive occlusions of a small branch of the left circumflex coronary artery resulted in reproducible reductions in MAP duration and a decrease in upstroke velocity. In a separate group (n=7), HMR 1883 (3 mg/kg i.v.) significantly (P<0.05) reduced the ischemia-induced shortening of the MAP: during the first and second control occlusion of the coronary artery in the HMR 1883-group, MAP50 duration shortened from 218.5 +/- 3.0 ms to 166.7 +/- 3.3 ms and from 219.7 +/- 4.5 ms to 164.9 +/- 1.8 ms, respectively. After HMR 1883, during the third occlusion, MAP duration decreased from 226.9 +/- 3.6 ms to 205.3 +/- 4.3 ms only corresponding to 59% inhibition. HMR 1883 also improved the upstroke velocity of the MAP, which was depressed by ischemia: in the two preceding control occlusions ischemia prolonged the time to peak of the MAP, an index for upstroke velocity, from 10.83 +/- 0.43 ms to 39.42 +/- 1.60 ms and from 12.97 +/- 0.40 ms to 37.17 +/- 2.98 ms, respectively. With HMR 1883, time to peak during ischemia rose from 12.42 +/- 0.51 ms to 25.53+/-2.51 ms only, corresponding to an average inhibitory effect of 53.4%. The irregular repolarisation contour of the ischemic MAP was also improved. In conclusion, the present results indicate that HMR 1883 effectively blocks myocardial KATP channels during coronary ischemia in anesthetised pigs, preventing an excessive shortening of the action potential and improving excitation propagation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10685870     DOI: 10.1007/s002109900166

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  10 in total

1.  Cardioselectivity of the sulphonylurea HMR 1098: studies on native and recombinant cardiac and pancreatic K(ATP) channels.

Authors:  Jocelyn E Manning Fox; Hussein D Kanji; Robert J French; Peter E Light
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 2.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

3.  HMR 1098 is not an SUR isotype specific inhibitor of heterologous or sarcolemmal K ATP channels.

Authors:  Hai Xia Zhang; Alejandro Akrouh; Harley T Kurata; Maria Sara Remedi; Jennifer S Lawton; Colin G Nichols
Journal:  J Mol Cell Cardiol       Date:  2010-12-23       Impact factor: 5.000

4.  Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs.

Authors:  Mohammad Sarraf; Li Lu; Shuyu Ye; Michael J Reiter; Clifford R Greyson; Gregory G Schwartz
Journal:  Cardiovasc Drugs Ther       Date:  2012-06       Impact factor: 3.727

5.  Precordial QT dispersion does not predict inducibility of ventricular tachyarrhythmias at post-revascularization electrophysiologic study.

Authors:  Satish R Raj; L Brent Mitchell; D George Wyse; Henry J Duff; Robert S Sheldon; Daniel Roach; Anne M Gillis
Journal:  J Interv Card Electrophysiol       Date:  2002-02       Impact factor: 1.900

Review 6.  KATP channels and cardiovascular disease: suddenly a syndrome.

Authors:  Colin G Nichols; Gautam K Singh; Dorothy K Grange
Journal:  Circ Res       Date:  2013-03-29       Impact factor: 17.367

7.  Inhibitors of ATP-sensitive potassium channels in guinea pig isolated ischemic hearts.

Authors:  A Weyermann; H Vollert; A E Busch; M Bleich; H Gögelein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-03-16       Impact factor: 3.000

8.  Glibenclamide and HMR1098 normalize Cantú syndrome-associated gain-of-function currents.

Authors:  Marien J C Houtman; Xingyu Chen; Muge Qile; Karen Duran; Gijs van Haaften; Anna Stary-Weinzinger; Marcel A G van der Heyden
Journal:  J Cell Mol Med       Date:  2019-05-22       Impact factor: 5.295

Review 9.  Ventricular Arrhythmias in First Acute Myocardial Infarction: Epidemiology, Mechanisms, and Interventions in Large Animal Models.

Authors:  Stefan Michael Sattler; Lasse Skibsbye; Dominik Linz; Anniek Frederike Lubberding; Jacob Tfelt-Hansen; Thomas Jespersen
Journal:  Front Cardiovasc Med       Date:  2019-11-05

Review 10.  Strategies for Pharmacological Organoprotection during Extracorporeal Circulation Targeting Ischemia-Reperfusion Injury.

Authors:  Aida Salameh; Stefan Dhein
Journal:  Front Pharmacol       Date:  2015-12-22       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.